Electra Therapeutics Readies IPO Launch On Positive Trial Results (Pending:ETRA)
· seekingalpha.com
Electra Therapeutics' lead asset, ipsoprubart, shows 100% early response/survival and FDA BTD. Review ETRA stock's risks, timeline, and value before investing.
Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs.He also leads the investing group IPO E...